🚀 Gate Square “Gate Fun Token Challenge” is Live!
Create tokens, engage, and earn — including trading fee rebates, graduation bonuses, and a $1,000 prize pool!
Join Now 👉 https://www.gate.com/campaigns/3145
💡 How to Participate:
1️⃣ Create Tokens: One-click token launch in [Square - Post]. Promote, grow your community, and earn rewards.
2️⃣ Engage: Post, like, comment, and share in token community to earn!
📦 Rewards Overview:
Creator Graduation Bonus: 50 GT
Trading Fee Rebate: The more trades, the more you earn
Token Creator Pool: Up to $50 USDT per user + $5 USDT for the first 50 launche
Research on the weight loss drug CagriSema by Noor and Noord
On February 5th, Jinshi Data reported that Novo Nordisk (NVO.N) stated on Wednesday that its new trial of the next generation obesity drug CagriSema will focus on dose escalation and the duration of the trial to further demonstrate the potential of the drug. In December of last year, the data of the drug disappointed the market, causing the company’s stock price to fall by 27%, which was one of the largest single-day declines for a European company. The CEO, Jorgensen, said that the company has confidence in the biological characteristics of this drug and is encouraged by what they see in the data.